Crizotinib in ROS1 rearranged non-small cell lung cancer (NSCLC), from response to resistance.

@article{Zhong2016CrizotinibIR,
  title={Crizotinib in ROS1 rearranged non-small cell lung cancer (NSCLC), from response to resistance.},
  author={Eric Zhong and Hua Huang},
  journal={BMJ case reports},
  year={2016},
  volume={2016}
}
We examined an immediate, but short-lived, response to crizotinib, a drug with a new indication for ROS1 rearranged non-small cell lung cancer (NSCLC) in a middle-aged non-smoker. The patient presented with metastatic NSCLC and extensive disease in multiple organs. He was treated with crizotinib 250 mg twice a day. Within 2-3 days, his condition rapidly improved, which was evident in a CT scan 2 months later. However, after 3 months of treatment, his condition deteriorated dramatically. The… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 22 extracted citations

Adenosquamous carcinoma of the lung

OncoTargets and therapy • 2018
View 1 Excerpt

Multiple primary lung cancer: A literature review.

Advances in clinical and experimental medicine : official organ Wroclaw Medical University • 2018

Similar Papers

Loading similar papers…